Yahoo
NasdaqGS - Nasdaq Real Time Price USD

CVRx, Inc. (CVRX)

1.3700 0.0000 (0.00%)
At close: October 22 at 4:00:01 PM EDT
1.3700 -0.0100 (-0.72%)
After hours: October 22 at 4:00:03 PM EDT
Trade CVRx on Coinbase
Chart Range Bar
Loading chart for CVRX
Chart does not reflect overnight price.
  • Previous Close 1.3700
  • Open 1.3700
  • Bid 1.3100 x 100
  • Ask 1.3900 x 200
  • Day's Range 1.3600 - 1.4200
  • 52 Week Range 1.2550 - 11.3000
  • Volume 247,559
  • Avg. Volume 935,023
  • Market Cap (intraday) 36.499M
  • Beta (5Y Monthly) 0.77
  • PE Ratio (TTM) --
  • EPS (TTM) -1.9700
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 4.58
  • Zacks Rating Neutral

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

www.barostim.com

223

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 10/22/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CVRX
80.70%
S&P 500 (^GSPC)
11.95%

1-Year Return

CVRX
86.20%
S&P 500 (^GSPC)
14.39%

3-Year Return

CVRX
89.39%
S&P 500 (^GSPC)
81.42%

5-Year Return

CVRX
91.22%
S&P 500 (^GSPC)
68.62%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 15.71M
Earnings -14.04M
Profit Margin -89.42%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-10M
0
10M
-85.0%
-80.0%
-75.0%

Analyst Insights

View More

Analyst Price Targets

3.50
4.58 Average
1.3700 Current
6.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/17/2026
Analyst Cantor Fitzgerald
Rating Action Maintains
Rating Overweight
Price Action Lowers
Price Target 13 -> 5

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    72.47M

  • Enterprise Value

    67.27M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.16

  • Price/Book (mrq)

    3.63

  • Enterprise Value/Revenue

    1.10

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -84.93%

  • Return on Assets (ttm)

    -28.70%

  • Return on Equity (ttm)

    -133.45%

  • Revenue (ttm)

    61.19M

  • Net Income Avi to Common (ttm)

    -51.97M

  • Diluted EPS (ttm)

    -1.9700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    64.59M

  • Total Debt/Equity (mrq)

    297.65%

  • Levered Free Cash Flow (ttm)

    -23.8M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.3700 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: